TLX Stock Overview
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Telix Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$6.92 |
| 52 Week High | AU$8.20 |
| 52 Week Low | AU$3.55 |
| Beta | 2.45 |
| 1 Month Change | 2.52% |
| 3 Month Change | 1.02% |
| 1 Year Change | 10.90% |
| 3 Year Change | 367.57% |
| 5 Year Change | 1,093.10% |
| Change since IPO | 798.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| TLX | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -3.1% | -1.4% | 0.6% |
| 1Y | 10.9% | 11.8% | 3.5% |
Return vs Industry: TLX underperformed the Australian Biotechs industry which returned 15.9% over the past year.
Return vs Market: TLX exceeded the Australian Market which returned 5.4% over the past year.
Price Volatility
| TLX volatility | |
|---|---|
| TLX Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 15.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: TLX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: TLX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Chris Behrenbruch | https://telixpharma.com |
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases.
Telix Pharmaceuticals Limited Fundamentals Summary
| TLX fundamental statistics | |
|---|---|
| Market Cap | AU$2.19b |
| Earnings (TTM) | -AU$118.89m |
| Revenue (TTM) | AU$28.73m |
76.2x
P/S Ratio-18.4x
P/E RatioIs TLX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLX income statement (TTM) | |
|---|---|
| Revenue | AU$28.73m |
| Cost of Revenue | AU$12.24m |
| Gross Profit | AU$16.49m |
| Other Expenses | AU$135.38m |
| Earnings | -AU$118.89m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 57.40% |
| Net Profit Margin | -413.76% |
| Debt/Equity Ratio | 0% |
How did TLX perform over the long term?
See historical performance and comparison